Agendia, Inc.: Agendia Research Shows Highest Risk MammaPrin

At the 2023 ASCO® Annual Meeting, Agendia will present data that demonstrates women within MammaPrint's highest risk category have the strongest sensitivity to chemotherapy and more aggressive tumor

Related Keywords

Dallas , Texas , United States , Kerry Harrington , William Audeh , Peter Beitsch , Agendia Mammaprint , Dallas Surgical Group , Facebook , Twitter , Agendia Inc , Linkedin , Annual Meeting , High Risk , Ultra Low , Chief Medical Officer , Print Index , Mammaprint High Risk , Surgical Oncologist , Dallas Surgical , Mammaprint High , Molecular Targets , Clinical Oncology , Agendia , Research , Shows , Highest , Risk , Mammaprint , Category , Redicts , Strongest , Hemosensitivity , Women , Early , Stage , Ther2 , Breast , Dancer ,